



Fig. S10 Anti-transferrin antibody treatment inhibits hypercoagulability *in vivo*.

HFD-fed *Apoe*^{-/-} mice were subjected to anti-transferrin antibody (Tf AB) or IgG treatment twice /week for 6 weeks. Plasma concentrations of transferrin (**a**), relative thrombin (**b**), and FXIIa activities (**c**) in plasma, APTT (**d**), PT (**e**), and tail-bleeding time (**f**) in *Apoe*^{-/-} mice are shown. Data represent mean ± SD (n = 6), **p < 0.01 by one-way ANOVA with Dunnett's post hoc test. N.S.: no significance; Tf: transferrin.